DCVC

Activity from announced rounds

All recorded activity

DCVC is an investment firm identified by TypeSafe AI as an existing investor and by its own communications as a backer of Shennon Biotechnologies.

Recorded funding activity

TypeSafe turns unstructured inputs into typed decisions and probability scores for automated software. Shennon develops T-cell engager therapies for solid tumors. Separate TypeSafe financings remain separate events under one investor history.

Sources
Rounds participated in
17
Confirmed lead rounds
4
7 roles undisclosed
New companies
16
First participation on record · 1 follow-on
Funding in participating rounds
$2.2B
15 disclosed · full round size, not this investor’s share

By stage

Series A5
Series C+4
Seed3
Series B3
Undisclosed2

By primary sector

Biotech4
AI3
Hardware3
Agritech2
Healthtech2
3 more
Climate tech1
Defense tech1
Enterprise software1

By country

United States11
United Kingdom4
Australia1
New Zealand1

Rounds

17 in all activity
Q-CTRL

Q-CTRL develops AI-powered control software for quantum computers and quantum navigation systems.

$290MSeries C
Participant
Remedy Robotics

Remedy Robotics develops AI-enabled robotic systems for endovascular procedures, aiming to extend specialist cardiovascular care to more hospitals.

$62MSeries B
Lead
BioStack

BioStack builds clinical data pipelines and realistic training environments for healthcare and drug-discovery AI.

$9.5MSeed
Lead
TypeSafe AI

Developer infrastructure that turns unstructured inputs into typed decisions and probability scores for automated software workflows.

$870MSeries A
Participant
Universal Quantum

Modular trapped-ion quantum computers built by connecting small quantum chips.

>$100MSeries A
Lead
Rainmaker

Rainmaker develops cloud-seeding technology and atmospheric research tools to increase freshwater supply.

$100MSeries B
Participant
TypeSafe AI

Developer infrastructure that turns unstructured inputs into typed decisions and probability scores for automated software workflows.

$40MSeed
Lead
Shennon Biotechnologies

Shennon Biotechnologies is developing precision T-cell engager immunotherapies for solid tumors.

$12MFunding
Participant
Callosum

Software infrastructure that optimises AI workloads across different models and computing architectures.

$100MSeed
Participant
Sabanto

Sabanto develops autonomous retrofit technology for agricultural equipment.

UndisclosedSeries B
Role not disclosed
Atom Computing

Develops large-scale neutral-atom quantum computers for fault-tolerant commercial and government applications

$100MSeries C
Role not disclosed
Quantum Motion

Builds utility-scale quantum computers using industry-standard silicon transistors

$160MSeries C
Role not disclosed
Kanvas Biosciences

Develops microbiome-based live biotherapeutics for cancer patients who do not respond to immunotherapy

$48MSeries A
Role not disclosed
Halter

Develops GPS-enabled cattle collars using sensors, software and AI.

$220MSeries E
Role not disclosed
Chariot Defense

Chariot Defense develops power-distribution systems for military use.

$34MSeries A
Role not disclosed
Proxima

Develops AI-driven drug discovery for proximity therapeutics

$80MUndisclosed
Role not disclosed
Alchemab Therapeutics

Alchemab Therapeutics develops antibody medicines by studying people resilient to disease.

£60MSeries A
Participant